Robeco Institutional Asset Management B.V. Acquires 5,389 Shares of IQVIA Holdings Inc. $IQV

Robeco Institutional Asset Management B.V. increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 181,263 shares of the medical research company’s stock after purchasing an additional 5,389 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.11% of IQVIA worth $40,858,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of IQV. Brighton Jones LLC boosted its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC boosted its holdings in IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in IQVIA during the second quarter valued at about $514,000. First Trust Advisors LP boosted its holdings in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after acquiring an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC boosted its holdings in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after acquiring an additional 1,155 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 2.8%

Shares of IQV opened at $171.98 on Tuesday. The stock has a market cap of $29.18 billion, a price-to-earnings ratio of 21.88, a P/E/G ratio of 1.62 and a beta of 1.39. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company has a 50-day moving average price of $172.19 and a two-hundred day moving average price of $204.28.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a report on Friday, March 6th. Jefferies Financial Group reduced their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Finally, Truist Financial reduced their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Buy” and a consensus price target of $226.63.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.